Danaher price target raised to $270 from $258 at BofA

BofA raised the firm’s price target on Danaher to $270 from $258 and keeps a Neutral rating on the shares after the company reported Q1 results ahead of expectations, with the firm highlighting “broad strength.” All in, the Q1 report shows “encouraging progress” from Danaher, but the firm awaits a broader and more consistent recovery in key markets beyond Bioprocessing, the analyst tells investors.